These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 18537180

  • 21. Precore stop codon mutation of hepatitis B virus is associated with low breakthrough rate following long-term lamivudine therapy.
    Shin JW, Chung YH, Choi MH, Kim JA, Ryu SH, Jang MK, Kim IS, Park NH, Lee HC, Lee YS, Suh DJ.
    J Gastroenterol Hepatol; 2005 Jun; 20(6):844-9. PubMed ID: 15946130
    [Abstract] [Full Text] [Related]

  • 22. Development of peptide nucleic acid mediated polymerase chain reaction clamping (PMPC)--direct sequencing method for detecting lamivudine-resistant hepatitis B virus (HBV) variants with high sensitivity and specificity.
    Ogata N, Ichida T, Aoyagi Y, Kitajima I.
    Rinsho Byori; 2003 Apr; 51(4):313-9. PubMed ID: 12747252
    [Abstract] [Full Text] [Related]

  • 23. Decreased infectivity of nucleoside analogs-resistant hepatitis B virus mutants.
    Billioud G, Pichoud C, Parent R, Zoulim F.
    J Hepatol; 2012 Jun; 56(6):1269-75. PubMed ID: 22314422
    [Abstract] [Full Text] [Related]

  • 24. Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants.
    Suzuki F, Akuta N, Suzuki Y, Sezaki H, Arase Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Matsuda M, Satoh J, Watahiki S, Kumada H.
    J Med Virol; 2006 Mar; 78(3):341-52. PubMed ID: 16419116
    [Abstract] [Full Text] [Related]

  • 25. Evolution of multi-drug resistant hepatitis B virus during sequential therapy.
    Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok AS.
    Hepatology; 2006 Sep; 44(3):703-12. PubMed ID: 16941700
    [Abstract] [Full Text] [Related]

  • 26. Effect of various pyrimidines possessing the 1-[(2-hydroxy-1-(hydroxymethyl)ethoxy)methyl] moiety, able to mimic natural 2'-deoxyribose, on wild-type and mutant hepatitis B virus replication.
    Kumar R, Semaine W, Johar M, Tyrrell DL, Agrawal B.
    J Med Chem; 2006 Jun 15; 49(12):3693-700. PubMed ID: 16759112
    [Abstract] [Full Text] [Related]

  • 27. The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication.
    Billioud G, Pichoud C, Puerstinger G, Neyts J, Zoulim F.
    Antiviral Res; 2011 Nov 15; 92(2):271-6. PubMed ID: 21871497
    [Abstract] [Full Text] [Related]

  • 28. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus.
    Wakil SM, Kazim SN, Khan LA, Raisuddin S, Parvez MK, Guptan RC, Thakur V, Hasnain SE, Sarin SK.
    J Med Virol; 2002 Nov 15; 68(3):311-8. PubMed ID: 12226816
    [Abstract] [Full Text] [Related]

  • 29. Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants.
    van der Eijk AA, Hansen BE, Niesters HG, Janssen HL, van de Ende M, Schalm SW, de Man RA.
    J Viral Hepat; 2005 Jul 15; 12(4):364-72. PubMed ID: 15985006
    [Abstract] [Full Text] [Related]

  • 30. The Interferon-Inducible Protein Tetherin Inhibits Hepatitis B Virus Virion Secretion.
    Yan R, Zhao X, Cai D, Liu Y, Block TM, Guo JT, Guo H.
    J Virol; 2015 Sep 15; 89(18):9200-12. PubMed ID: 26109732
    [Abstract] [Full Text] [Related]

  • 31. Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B.
    Yeh CT, Chen T, Hsu CW, Chen YC, Lai MW, Liang KH, Chen TC.
    BMC Cancer; 2011 Sep 21; 11():398. PubMed ID: 21933446
    [Abstract] [Full Text] [Related]

  • 32. The rtL229 substitutions in the reverse transcriptase region of hepatitis B virus (HBV) polymerase are potentially associated with lamivudine resistance as a compensatory mutation.
    Ji D, Liu Y, Li L, Xu Z, Si LL, Dai JZ, Li X, Wang L, Yao Z, Xin SJ, Chen GF, Xu D.
    J Clin Virol; 2012 May 21; 54(1):66-72. PubMed ID: 22398037
    [Abstract] [Full Text] [Related]

  • 33. [Evolution of hepatitis B virus quasispecies during antiviral therapy in one chronic hepatitis B patient].
    Liang PP, Guo JJ, Li QL, Luo Q, Shi XF, Huang AL.
    Zhonghua Gan Zang Bing Za Zhi; 2011 Jul 21; 19(7):516-20. PubMed ID: 22152243
    [Abstract] [Full Text] [Related]

  • 34. Antiviral drug-associated potential vaccine-escape hepatitis B virus mutants in Turkish patients with chronic hepatitis B.
    Sayan M, Akhan SC.
    Int J Infect Dis; 2011 Oct 21; 15(10):e722-6. PubMed ID: 21784687
    [Abstract] [Full Text] [Related]

  • 35. The short hairpin RNA driven by polymerase II suppresses both wild-type and lamivudine-resistant hepatitis B virus strains.
    Ren GL, Fang Y, Ma HH, Lei YF, Wang D, Xu MC, Wang PZ, Huang CX, Nie OH, Sun YT, Bai XF.
    Antivir Ther; 2007 Oct 21; 12(6):865-76. PubMed ID: 17926641
    [Abstract] [Full Text] [Related]

  • 36. Do different lamivudine-resistant hepatitis B genotypes carry the same risk of entecavir resistance?
    Lee GH, Aung MO, Dan YY, Lee YM, Mak B, Low HC, Lim K, Thwin MA, Tan PS, Lim SG.
    J Med Virol; 2013 Jan 21; 85(1):26-33. PubMed ID: 23023992
    [Abstract] [Full Text] [Related]

  • 37. Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs.
    Salpini R, Svicher V, Cento V, Gori C, Bertoli A, Scopelliti F, Micheli V, Cappiello T, Spanò A, Rizzardini G, De Sanctis GM, Sarrecchia C, Angelico M, Perno CF.
    Antiviral Res; 2011 Nov 21; 92(2):382-5. PubMed ID: 21920388
    [Abstract] [Full Text] [Related]

  • 38. Identification of rare polymerase variants of hepatitis B virus using a two-stage PCR with peptide nucleic acid clamping.
    Ohishi W, Shirakawa H, Kawakami Y, Kimura S, Kamiyasu M, Tazuma S, Nakanishi T, Chayama K.
    J Med Virol; 2004 Apr 21; 72(4):558-65. PubMed ID: 14981758
    [Abstract] [Full Text] [Related]

  • 39. Evaluation of novel strategies to combat hepatitis B virus targetting wild-type and drug-resistant mutants in experimental models.
    Zoulim F.
    Antivir Chem Chemother; 2001 Apr 21; 12 Suppl 1():131-42. PubMed ID: 11594680
    [Abstract] [Full Text] [Related]

  • 40. Stop codons in the hepatitis B surface proteins are enriched during antiviral therapy and are associated with host cell apoptosis.
    Colledge D, Soppe S, Yuen L, Selleck L, Walsh R, Locarnini S, Warner N.
    Virology; 2017 Jan 15; 501():70-78. PubMed ID: 27871021
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.